Search research articles
Contact Us
Filters
Showing results (101-110 of 205) with videos related to
Page
of 21
Sort By:
Blood Neoplasia
|
June 2, 2025
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib
Chung Hoow Kok, Yazad Irani, Jade Clarson, et al.
Haematologica
|
February 4, 2017
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells
Jueqiong Wang, Liu Lu, Chung H Kok, et al.
British Journal of Haematology
|
May 27, 2022
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
Liu Lu, Chung Hoow Kok, Phuong Dang, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 13, 2012
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects
Kate Vandyke, Stephen Fitter, Jenny Drew, et al.
Cancer Genetics
|
October 14, 2017
A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH
Teresa Sadras, Susan L Heatley, Chung H Kok, et al.
Blood Advances
|
January 9, 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
Yazad D Irani, Chung H Kok, Jade Clarson, et al.
British Journal of Haematology
|
July 24, 2023
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha
Yazad D Irani, Amy Hughes, Chung H Kok, et al.
Blood
|
November 29, 2007
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter, Andrea L Dewar, Panagiota Kostakis, et al.
Blood
|
March 21, 2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Susan Branford, David T Yeung, Jodi A Prime, et al.
Leukemia & Lymphoma
|
January 4, 2021
<i>In-vitro</i> modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene <i>RANBP2-ABL1</i> - implications for targeted therapy
Susan L Heatley, Kartini Asari, Caitlin E Schutz, et al.
Page
of 21
Search research articles
Search
Showing results (101-110 of 205) with videos related to
Sort By:
Page
of 21
Blood Neoplasia
|
June 2, 2025
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib
Chung Hoow Kok, Yazad Irani, Jade Clarson, et al.
Haematologica
|
February 4, 2017
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells
Jueqiong Wang, Liu Lu, Chung H Kok, et al.
British Journal of Haematology
|
May 27, 2022
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission
Liu Lu, Chung Hoow Kok, Phuong Dang, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 13, 2012
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects
Kate Vandyke, Stephen Fitter, Jenny Drew, et al.
Cancer Genetics
|
October 14, 2017
A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH
Teresa Sadras, Susan L Heatley, Chung H Kok, et al.
Blood Advances
|
January 9, 2023
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
Yazad D Irani, Chung H Kok, Jade Clarson, et al.
British Journal of Haematology
|
July 24, 2023
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha
Yazad D Irani, Amy Hughes, Chung H Kok, et al.
Blood
|
November 29, 2007
Long-term imatinib therapy promotes bone formation in CML patients
Stephen Fitter, Andrea L Dewar, Panagiota Kostakis, et al.
Blood
|
March 21, 2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Susan Branford, David T Yeung, Jodi A Prime, et al.
Leukemia & Lymphoma
|
January 4, 2021
<i>In-vitro</i> modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene <i>RANBP2-ABL1</i> - implications for targeted therapy
Susan L Heatley, Kartini Asari, Caitlin E Schutz, et al.
Page
of 21